Salute e Benessere

BBS-Bioactive Bone Substitutes Plc – Inside information – Positive decision…

BBS-Bioactive Bone Substitutes Plc, Company announcement, Insider information, 26 May 2023 at 5:30 p.m. EESTBBS-Bioactive Bone Substitutes Plc – Inside information – Positive decision received on the product classification, schedule for the quality system approval to be updated BBS-Bioactive Bone Substitutes Plc has received information today that the Notified Body has approved ARTEBONE® Paste's product classification as a medical device. The product classification decision is a part of...
Nasdaq GlobeNewswire
26/05/2023

Pulse Medical receives FDA Breakthrough Device Designation for its μFR® system

The μFR is an angio-based physiological assessment tool without a pressure wire or hyperemic agents. It has a wider range of indications and is more affordable. μFR® can be used throughout the entire PCI procedure, including precise physiology assessment at Pre-PCI, strategy optimization during the operation, outcome and microcirculatory function assessment at Post-PCI. The μFR is an angio-based physiological assessment tool without a pressure wire or hyperemic agents. It has a wider range of...
PR Newswire
26/05/2023

Resolutions of Bioretec Ltd´s Annual General Meeting and the constitutive…

The Annual General Meeting resolved in accordance with the proposal of the Board of Directors that the loss of EUR 2,347,332.35 for the financial period 1 January-31 December 2022 will be booked in the balance sheet as equity under profit/loss for previous financial periods and that no dividend shall be distributed. The Annual General Meeting resolved in accordance with the proposal of the Board of Directors that the loss ofEUR 2,347,332.35for the financial period 1 January- 31 December...
PR Newswire
26/05/2023

Novavax's Nuvaxovid™ Receives Positive CHMP Opinion for Full Marketing…

Novavax has demonstrated the efficacy and safety of Nuvaxovid as a primary series, and the immunogenicity and safety of the vaccine as a booster in individuals aged 12 and older in the Phase 3 PREVENT-19 trial, Phase 2 trials and in real-world evidence. Novavax has demonstrated the efficacy and safety of Nuvaxovid as a primary series, and the immunogenicity and safety of the vaccine as a booster in individuals aged 12 and older in the Phase 3 PREVENT-19 trial, Phase 2 trials and in real-world…
PR Newswire
26/05/2023

BerGenBio ASA: Approval and publication of prospectus for the preferential…

The Financial Supervisory Authority of Norway (Nw: Finanstilsynet) has today, 26 May 2023, approved a prospectus prepared by the Company in connection with the Rights Issue (the "Prospectus") and the listing of between 1,687,500,000 and 2,500,000,000 offer shares in the Rights Issue. Subject to local applicable securities laws, the Prospectus will be made available at the websites of the Company (https://www.bergenbio.com), as well as the websites of Carnegie AS…
PR Newswire
26/05/2023

The Global Metastatic Breast Cancer Treatment Market Expected To Reach $31…

It added: "The rising investments in research and development by various manufacturing companies and increasing awareness programs on cancer diagnostics are likely to help this market witness significant growth opportunities in the years to come. It concluded: "Regionally, North America held the dominant share in the global metastatic breast cancer market owing to the presence of well-established healthcare infrastructure, availability of advanced facilities, and best medical…
PR Newswire
26/05/2023

Ipsen receives CHMP negative opinion, following re-examination of potential…

Palovarotene is the first medicine to be submitted for regulatory approval for fibrodysplasia ossificans progressiva (FOP), an ultra-rare disease with an estimated prevalence of 1.36 per million individuals and around 900 people diagnosed worldwide. 1,2 FOP continuously and permanently causes abnormal bone formation, 3leading to progressive mobility loss and shortened life expectancyThere are currently no disease-modifying treatment options available in the E.U.Regulatory processes...
Nasdaq GlobeNewswire
26/05/2023

Bulletin from the Annual General Meeting in Immunovia AB

The AGM resolved that the company's available profits, SEK 127,985,141, shall be brought forward and that no dividend shall be made. The board of directors and the managing directors were discharged from liability for the financial year 2022. The AGM resolved that the company's available profits,SEK 127,985,141, shall be brought forward and that no dividend shall be made. The board of directors and the managing directors were discharged from liability for the financial year 2022. Fees...
PR Newswire
26/05/2023

Data Demonstrating Long-Term Improvement in Depression in Cancer Patients…

More than half of the patients demonstrated remission of depression at 18 months, after a single dose of 25mg investigational COMP360 psilocybin with psychological supportOpen label phase 2 study, conducted by Sunstone Therapies and scheduled to be presented at the ASCO annual meeting on June 5, is believed to be the longest clinical study of psilocybin ever conductedLONDON, May26, 2023(GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care...
Nasdaq GlobeNewswire
26/05/2023

Menarini Group Shares New Analysis from EMERALD Clinical Study of ORSERDU®…

ESR1 mutations are present in up to 40% of ER+, HER2- advanced or metastatic breast cancers, and they are a known driver of resistance to standard endocrine therapy. ESR1mutations are present in up to 40% of ER+, HER2- advanced or metastatic breast cancers, and they are a known driver of resistance to standard endocrine therapy. Importantly, a previous subgroup analysis of the EMERALD PFS results, which were presented at the San Antonio Breast Cancer Symposium (SABCS) 2022…
PR Newswire
26/05/2023

Tridentify launches a unique real-time monitoring and decision-support system…

With the launch of this new monitoring system, Tridentify is revolutionising the industry by enabling companies to monitor their operations and the stability of their shipments in real time. The new system provides an accurate and real-time overview of a shipment's stability and remaining lifespan, allowing companies to make data-driven decisions with confidence. By implementing this system, companies can ensure they are working within their given framework and can also identify areas of…
PR Newswire
26/05/2023

Bring to Life 1890s Vienna & Elegant Functionalism In Your Own Home -…

Established in 2019, Marano Furniture aims to revolutionise the conventions of furniture design by bringing together young designers across Asia to create innovative thematic pieces made with quality craftsmanship, while showcasing their works on a global platform. Established in 2019, Marano Furniture aims to revolutionise the conventions of furniture design by bringing together young designers acrossAsiato create innovative thematic pieces made with quality craftsmanship, while showcasing...
PR Newswire
26/05/2023

Global Idiopathic Gastroparesis Drugs Market to Surpass USD 1782 Million By 2031…

Download PDF Sample here: https://growthmarketreports.com/request-sample/5065 Download PDF Sample here: https://growthmarketreports.com/request-sample/5065 The report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics of the industry. It provides an in-depth analysis of the market segments which include drug, route of administration, distribution channel, and competitor analysis. This report also...
PR Newswire
26/05/2023

Navamedic to own a total of 96.33 per cent of shares in Sensidose following…

"We are excited by the prospect of becoming the owner of Sensidose. Our next step will be to add Sensidose's unique Parkinson's treatment to our existing marketing and distribution channels and rapidly ramp up commercialisation efforts in the Nordics. "We are excited by the prospect of becoming the owner of Sensidose. Our next step will be to add Sensidose's unique Parkinson's treatment to our existing marketing and distribution channels and rapidly ramp up commercialisation efforts in…
PR Newswire
26/05/2023

Vivoryon Therapeutics Successfully Completes Private Placement Raising EUR 25…

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY,IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, CANADA,JAPAN, AUSTRALIA, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE THEDISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOTCONSTITUTE OR FORM AN OFFER FOR SALE OF, OR THE SOLICITATION OF AN OFFERTO BUY, THE SECURITIES REFERRED TO HEREIN IN ANY JURISDICTION,INCLUDING THE UNITED STATES, CANADA, AUSTRALIA, SOUTH AFRICA, JAPAN ORANY...
Nasdaq GlobeNewswire
26/05/2023

Sequana Medical announces Special General Meeting of Shareholders on 26 June…

PRESS RELEASE REGULATED INFORMATION26 May 2023 , 07:00 am CESTGhent, Belgium – 26May 2023– Sequana Medical NV (Euronext Brussels: SEQUA)(the " Company " or " SequanaMedical "), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, today invites the holders of securities issued by the Company to attend the Special General Meeting of Shareholders on Monday, 26 June 2023.The items on the agendas of the meeting...
Nasdaq GlobeNewswire
26/05/2023

Groupe Casino : Initiation of conciliation procedure

Initiation of conciliation procedure Paris, 26 May 2023Further to its press releases of 24 April 2023, the Casino group has received the consent of the senior secured lenders under its Term Loan B Facility and Revolving Credit Facility (“RCF”) as well as the Quatrim secured bonds 1and the unsecured bonds issued by Casino and subject to New York law (coming due in 2026 [code: XS2276596538] and 2027 [code: XS2328426445]) in order to request the appointment of conciliators ( conciliateurs...
Nasdaq GlobeNewswire
26/05/2023

Groupe Casino : Groupement Les Mousquetaires and Casino group sign a protocol to…

Groupement Les Mousquetaires and Casino group sign a protocolto extend the scope of their partnerships and optimize their respective networks Paris, 26 May 2023Following exclusive discussions on 24 April 2023, Groupement Les Mousquetaires and Casino group today signed a protocol of intent that deepens and significantly extends their industrial and purchasing partnerships, and optimizes their respective networks.Under this protocol, Groupement Les Mousquetaires and Casino...
Nasdaq GlobeNewswire
26/05/2023

Bulletin from the Annual General Meeting of Implantica AG

The general meeting resolved to carry forward the net loss for the financial year 2022 in accordance with the adopted balance sheet and to no payment of dividend. The general meeting resolved to carry forward the net loss for the financial year 2022 in accordance with the adopted balance sheet and to no payment of dividend. The general meeting resolved to discharge the members of the board of directors, the executive management and the auditors from liability for their services in the...
PR Newswire
26/05/2023

LG INSTAVIEW FRIDGE TO LIFT THE 'MOODUP' AT VIVID SYDNEY 2023

A truly revolutionary kitchen appliance, the LG InstaView fridge with MoodUP has color-changing door panels that provide a whole new level of personalization. Enabling users to switch up the colors whenever the mood takes them, the fridge and its LED panels offer up to 190,000[1] color combinations to choose from and easy management via the LG ThinQ™ mobile app. Additionally, the InstaView with MoodUP boasts advanced refrigeration and smart technologies that deliver outstanding food freshness…
PR Newswire
26/05/2023

Huma named for its successful and innovative approach to clinical trials in new…

The review proposes that the government doubles the numbers of people taking part in commercial clinical trials in the next two years, and doubles it again by 2027. One of its 27 recommendations is the support and promotion of decentralised clinical trials, which are enabled by digital technology. It calls on stakeholders to develop guidance for decentralised and innovative trials by the end of 2023 to keep pace internationally. The review proposes that the government doubles the numbers of...
PR Newswire
26/05/2023

Daewoong Pharmaceutical Publishes Molecular Mechanism of Bersiporocin as an…

Bersiporocin inhibits catalytic activity of PARS1(Prolyl-tRNA Synthetase1 or PRS) which is involved in collagen synthesis. There have been studies to inhibit PARS1 catalytic activity as an antifibrotic, yet the challenge was modulating the potency of PARS1 enzymatic inhibition as it is a critical enzyme for protein production. Daewoong has been trying to overcome the hurdle by inhibiting PARS1 just enough to bring therapeutic benefits without compromising safety. Through this publication, it has…
PR Newswire
26/05/2023

Oncolytics Biotech® Announces Positive Randomized Phase 2 Data from BRACELET-1…

Oncolytics to advance to registrational study of pelareorep-paclitaxel combination in HR+/HER2- breast cancer Oncolytics to advance to registrational study of pelareorep-paclitaxel combination in HR+/HER2- breast cancer SAN DIEGOandCALGARY, AB,May 25, 2023/PRNewswire/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced positive results from BRACELET-1, a randomized phase 2 trial in HR+/HER2- metastatic breast cancer. The results are published in an abstract...
PR Newswire
25/05/2023

Genmab Announces Multiple Abstracts to be Presented at the American Society of…

Media ReleaseCOPENHAGEN, Denmark; May 25 , 2023 Oral presentations will highlightepcoritamab-byspin combination withrituximab-lenalidomide (R2) in high-risk follicular lymphomaPoster presentationswill highlight epcoritamabin lymphomaacross multiple lines of therapy and histologieswhere high unmet needs exist Genmab A/S (Nasdaq:GMAB)announced today that multiple abstracts evaluating epcoritamab, a T-cell engaging...
Nasdaq GlobeNewswire
25/05/2023
Altri  Comunicati